Investor Presentaiton

Major R&D Milestones (Next Wave) Project VANFLYTAⓇ EZHARMIA® DS-1103 DS-3939 Target Indication [phase, study name] • AML, 1L [Ph3, QUANTUM-First] Daiichi-Sankyo As of Jul 2023 FY2023 FY2024 H1 H2 • Approved (JP/US) • Approval anticipated (EU) ⚫r/r PTCL [Registrational Ph2, VALENTINE-PTCL01] • HER2 expressing or mutant solid tumors, HER2 low BC [Ph1] Solid tumors [Ph1/2] • TLR obtained • Study started Study start planned DS-1471 · Solid tumors [Ph1] DS-7011 DS-5670 • ⚫ Systemic lupus erythematosus [Ph1b/2] • COVID-19 mRNA vaccine (mutant strain), booster vaccination [Ph3] • ⚫ Study started • Study started • Study start planned Bold: update from FY2022 Q4 • COVID-19 mRNA vaccine (original strain), booster vaccination [Ph1/2/3] • Approval anticipated (JP) AML: acute myeloid leukemia, BC: breast cancer, PTCL: peripheral T cell lymphoma, r/r: relapsed/refractory, TLR: top line results Timeline indicated is based on the current forecast and subject to change 34

View entire presentation